Semaglutide [Ozempik] Injection Pen

Description

Semaglutide for Weight Loss and Type 2 Diabetes Research

Semaglutide is a widely studied GLP-1 receptor agonist being explored in research settings for its potential to support weight loss and manage type 2 diabetes. Known under the brand names Ozempic® and Wegovy®, semaglutide works by mimicking a natural hormone that may help regulate blood sugar levels and appetite.

Key Research Findings

• May lower HbA1c (a marker of blood sugar) by 1–1.5%

• May support up to 15% body weight reduction over several months

• Shown to improve metabolic health in various clinical trials

Note: This information is based on clinical research and is intended for educational purposes only. It does not constitute medical advice or product claims. Always consult a licensed healthcare professional for personal medical decisions.

The semaglutide sold here is for research use only. It is not intended for human consumption.

---

Semaglutide Dosing (Research Use Only)

In research studies, semaglutide dosing typically follows a gradual escalation to improve tolerance:

• Starting dose: 0.25 mg weekly via subcutaneous injection

• Titration: Gradually increased over time to 1 mg or up to 2.4 mg weekly, depending on study protocols

• Injection sites: Abdomen, thigh, or upper arm (rotate injection sites regularly)

• Form: Usually administered via pre-filled pens in clinical or research settings

---

Semaglutide Side Effects (As Reported in Studies)

Common side effects:

• Nausea

• Vomiting

• Diarrhea

• Constipation

These are most common in the early stages and may decrease over time.

Rare but serious risks:

• Pancreatitis

• Gallbladder issues

This side effect profile is based on published clinical trial data and may vary. Not all effects are known outside controlled study environments.